Literature DB >> 23760244

High levels of CD2 expression identify HIV-1 latently infected resting memory CD4+ T cells in virally suppressed subjects.

Maria Iglesias-Ussel1, Claire Vandergeeten, Luigi Marchionni, Nicolas Chomont, Fabio Romerio.   

Abstract

Resting memory CD4(+) T cells are the largest reservoir of persistent infection in HIV-1-positive subjects. They harbor dormant, stably integrated virus despite suppressive antiretroviral therapy, posing an obstacle to a cure. Surface markers that identify latently infected cells remain unknown. Microarray analyses comparing resting latently infected and uninfected CD4(+) T cells generated in vitro showed profound differences in the expression of gene programs related to transcriptional and posttranscriptional regulation, cell proliferation, survival, cycle progression, and basic metabolism, suggesting that multiple biochemical and metabolic blocks contribute to preventing viral production in latently infected cells. We identified 33 transcripts encoding cell surface markers that are differentially expressed between latently infected and uninfected cells. Quantitative reverse transcriptase PCR (RT-QPCR) and flow cytometry analyses confirmed that the surface marker CD2 was expressed at higher levels on latently infected cells. To validate this result in vivo, we sorted resting memory CD4(+) T cells expressing high and low surface levels of CD2 from six HIV-1-infected subjects successfully treated with antiretroviral drugs for at least 3 years. Resting memory CD4(+) CD2(high) T cells from all subjects harbored higher HIV-1 DNA copy numbers than all other CD4(+) T cell subsets. Moreover, after ex vivo viral reactivation, robust viral RNA production was detected only from resting memory CD4(+) CD2(high) T cells but not from other cell subsets. Altogether, these results show that a high CD2 expression level is a hallmark of latently infected resting memory CD4(+) T cells in vivo.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23760244      PMCID: PMC3754042          DOI: 10.1128/JVI.01297-13

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  85 in total

Review 1.  HIV reservoirs, latency, and reactivation: prospects for eradication.

Authors:  Viktor Dahl; Lina Josefsson; Sarah Palmer
Journal:  Antiviral Res       Date:  2009-10-04       Impact factor: 5.970

Review 2.  Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs.

Authors:  Mayte Coiras; María Rosa López-Huertas; Mayte Pérez-Olmeda; José Alcamí
Journal:  Nat Rev Microbiol       Date:  2009-11       Impact factor: 60.633

3.  Identification of a potential pharmacological sanctuary for HIV type 1 in a fraction of CD4(+) primary cells.

Authors:  Antonio Valentin; Matthew Morrow; Richard H Poirier; Karen Aleman; Richard Little; Robert Yarchoan; George N Pavlakis
Journal:  AIDS Res Hum Retroviruses       Date:  2010-01       Impact factor: 2.205

4.  Safety profile and clinical outcomes in a phase I, placebo-controlled study of siplizumab in acute graft-versus-host disease.

Authors:  Douglas Adkins; Voravit Ratanatharathorn; Harry Yang; Barbara White
Journal:  Transplantation       Date:  2009-07-27       Impact factor: 4.939

5.  Safety profile, pharmacokinetics, and pharmacodynamics of siplizumab, a humanized anti-CD2 monoclonal antibody, in renal allograft recipients.

Authors:  T L Pruett; R W McGory; F H Wright; M D Pescovitz; H Yang; J B McClain
Journal:  Transplant Proc       Date:  2009-11       Impact factor: 1.066

6.  Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation.

Authors:  Hung-Chih Yang; Sifei Xing; Liang Shan; Karen O'Connell; Jason Dinoso; Anding Shen; Yan Zhou; Cynthia K Shrum; Yefei Han; Jun O Liu; Hao Zhang; Joseph B Margolick; Robert F Siliciano
Journal:  J Clin Invest       Date:  2009-10-01       Impact factor: 14.808

7.  HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation.

Authors:  Nicolas Chomont; Mohamed El-Far; Petronela Ancuta; Lydie Trautmann; Francesco A Procopio; Bader Yassine-Diab; Geneviève Boucher; Mohamed-Rachid Boulassel; Georges Ghattas; Jason M Brenchley; Timothy W Schacker; Brenna J Hill; Daniel C Douek; Jean-Pierre Routy; Elias K Haddad; Rafick-Pierre Sékaly
Journal:  Nat Med       Date:  2009-06-21       Impact factor: 53.440

8.  In vitro nuclear interactome of the HIV-1 Tat protein.

Authors:  Virginie W Gautier; Lili Gu; Niaobh O'Donoghue; Stephen Pennington; Noreen Sheehy; William W Hall
Journal:  Retrovirology       Date:  2009-05-19       Impact factor: 4.602

9.  Cellular levels of HIV unspliced RNA from patients on combination antiretroviral therapy with undetectable plasma viremia predict the therapy outcome.

Authors:  Alexander O Pasternak; Suzanne Jurriaans; Margreet Bakker; Jan M Prins; Ben Berkhout; Vladimir V Lukashov
Journal:  PLoS One       Date:  2009-12-31       Impact factor: 3.240

10.  Epigenetic regulation of HIV-1 latency by cytosine methylation.

Authors:  Steven E Kauder; Alberto Bosque; Annica Lindqvist; Vicente Planelles; Eric Verdin
Journal:  PLoS Pathog       Date:  2009-06-26       Impact factor: 6.823

View more
  45 in total

1.  Experimental Approaches for Eliminating Latent HIV.

Authors:  Matthew D Marsden; Jerome A Zack
Journal:  For Immunopathol Dis Therap       Date:  2015

Review 2.  Barriers for HIV Cure: The Latent Reservoir.

Authors:  Sergio Castro-Gonzalez; Marta Colomer-Lluch; Ruth Serra-Moreno
Journal:  AIDS Res Hum Retroviruses       Date:  2018-08-28       Impact factor: 2.205

Review 3.  Impact of Myeloid Reservoirs in HIV Cure Trials.

Authors:  Brooks I Mitchell; Elizabeth I Laws; Lishomwa C Ndhlovu
Journal:  Curr HIV/AIDS Rep       Date:  2019-04       Impact factor: 5.071

Review 4.  Eradicating HIV-1 infection: seeking to clear a persistent pathogen.

Authors:  Nancie M Archin; Julia Marsh Sung; Carolina Garrido; Natalia Soriano-Sarabia; David M Margolis
Journal:  Nat Rev Microbiol       Date:  2014-11       Impact factor: 60.633

5.  Humanized Mouse Model of HIV-1 Latency with Enrichment of Latent Virus in PD-1+ and TIGIT+ CD4 T Cells.

Authors:  George N Llewellyn; Eduardo Seclén; Stephen Wietgrefe; Siyu Liu; Morgan Chateau; Hua Pei; Katherine Perkey; Matthew D Marsden; Sarah J Hinkley; David E Paschon; Michael C Holmes; Jerome A Zack; Stan G Louie; Ashley T Haase; Paula M Cannon
Journal:  J Virol       Date:  2019-05-01       Impact factor: 5.103

6.  Expression of HIV-1 matrix protein p17 and association with B-cell lymphoma in HIV-1 transgenic mice.

Authors:  Virginia A Carroll; Mark K Lafferty; Luigi Marchionni; Joseph L Bryant; Robert C Gallo; Alfredo Garzino-Demo
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-31       Impact factor: 11.205

Review 7.  Targeting HIV latency: resting memory T cells, hematopoietic progenitor cells and future directions.

Authors:  Nadia T Sebastian; Kathleen L Collins
Journal:  Expert Rev Anti Infect Ther       Date:  2014-09-04       Impact factor: 5.091

8.  Kinase control of latent HIV-1 infection: PIM-1 kinase as a major contributor to HIV-1 reactivation.

Authors:  Alexandra Duverger; Frank Wolschendorf; Joshua C Anderson; Frederic Wagner; Alberto Bosque; Takao Shishido; Jennifer Jones; Vicente Planelles; Christopher Willey; Randall Q Cron; Olaf Kutsch
Journal:  J Virol       Date:  2013-10-23       Impact factor: 5.103

9.  Myeloid Dendritic Cells Induce HIV Latency in Proliferating CD4+ T Cells.

Authors:  Nitasha A Kumar; Renee M van der Sluis; Talia Mota; Rachel Pascoe; Vanessa A Evans; Sharon R Lewin; Paul U Cameron
Journal:  J Immunol       Date:  2018-07-20       Impact factor: 5.422

10.  Identification of glycoproteins associated with HIV latently infected cells using quantitative glycoproteomics.

Authors:  Weiming Yang; Brooks Jackson; Hui Zhang
Journal:  Proteomics       Date:  2016-06-08       Impact factor: 3.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.